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increasing interest in a minimally invasive approach (ie,
PTRA) by both physicians and patients alike. With the
increasing involvement of cardiologists in the percuta-
neous management of peripheral vascular problems, it is
incumbent on vascular surgeons to evaluate the efficacy of
these interventions.
The first PTRA was reported in 1978 by Grüntzig et
al.3 There have been numerous studies of renal angio-
plasty, including a large series from our institution.2 In
1992 we reported the long-term clinical results of 110
patients after balloon angioplasty alone of atherosclerotic
renal ostial lesions. After comparing our outcomes with a
control cohort of 94 patients with nonostial stenoses and
finding no differences, we concluded that PTRA is bene-
ficial in the control of renovascular hypertension when
used to treat both ostial and nonostial lesions. Our con-
clusion that ostial renal artery stenoses are not a con-
traindication to angioplasty differed from earlier reports
from our institution and from others.4-9 As experience has
increased with treatment of these lesions, as well as patient
selection bias, so will results improve.10-13 The position
that physicians should take a more aggressive approach to
the treatment of renal artery stenoses can be supported
only if the interventions are safe, effective, and durable.
Compared with conventional surgery, PTRA is a simple
procedure associated with a low morbidity rate and has
Renal artery stenoses are clinically significant lesions
because of their potential to compromise renal function
and lead to or exacerbate hypertension. Recent data have
been accumulated on the progressive natural history of
renal artery stenoses and deterioration of renal function.1
A more liberal approach to percutaneous transluminal
renal angioplasty (PTRA) has been advocated for the
treatment of renal artery stenosis.2 Complicating the deci-
sion to intervene is the fact that some lesions appear to
have no clinical sequelae.
Although there are numerous surgical options avail-
able for the treatment of renal artery stenoses, the dura-
bility of which has been clearly demonstrated, there is
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Purpose: The natural history of renal artery stenosis is progression with subsequent deterioration of kidney function
and development of renovascular hypertension. Percutaneous transluminal renal angioplasty is effective in the treat-
ment of nonostial lesions but less effective for ostial stenoses. Because of the poor technical success experienced with
percutaneous transluminal renal angioplasty, stenting of ostial stenoses is becoming the standard of endovascular care.
In this retrospective study we analyzed the technical and clinical outcomes after renal artery stenting in 73 consecutive
patients.
Patients and Methods: From July 1992 to January 1999, 88 Palmaz stents were deployed in 85 renal artery stenoses in
73 patients, with a mean age of 67.9 ± 9.4 years. Twelve patients (16%) underwent bilateral stent placement.
Atheromatous lesions were the most prevalent (99%: 82% ostial, 16% nonostial). Most stents were implanted for sub-
optimal balloon dilation (52%) or dissection (24%). Mean percent stenosis was 86% ± 12%. Renal insufficiency (creati-
nine level ≥ 1.5 mg/dL) was present in 50 (68%) patients, and uncontrolled hypertension (systolic ≥ 160 mm Hg or
diastolic ≥ 90 mm Hg with more than two medications) was present in 57 (78%).
Results: Primary technical success was achieved in 89%. At the initial procedure, three additional stents were placed for
residual stenoses, and urokinase was used to treat one intraprocedural stent thrombosis, resulting in an assisted pri-
mary technical success rate of 94%. Major complications occurred in 9.1% of stents placed: access artery thrombosis (n
= 4), renal artery extravasation (n = 1), renal artery thrombosis (n = 1), and hematoma requiring operation (n = 2).
Long-term clinical data were available on 69 (95%) patients at 20 ± 17 months. Overall, a significant decrease in sys-
tolic and diastolic pressures (P < .001) and reduction of medication (P < .01) were noted without a change in renal
function (P = NS). Angiography was performed on 22 patients at 11.3 ± 10.3 months for persistent or worsening renal
function or hypertension or for other reasons; 10 patients had significant restenoses in 14 renal arteries.
Conclusion: Our retrospective analysis demonstrates that endovascular stenting of renal artery stenosis in patients with
poorly controlled hypertension or deteriorating renal function is a safe and effective alternative treatment to surgical
management. (J Vasc Surg 2001;33:1041-9.)
been shown to have a high immediate technical success
rate2,5,14,15; however, the restenosis rate has been unsatis-
factory. In a review by Martin et al,14 the incidence of
restenosis after a technically successful PTRA was 30%.
Furthermore, this same incidence was demonstrated in a
prospective trial by Weibull et al.15 High restenosis rates
occur after the treatment of atherosclerotic ostial lesions
because they, in fact, represent an extension of severe aor-
tic atheromatous disease. In 1987 Palmaz et al10 intro-
duced stenting of the renal arteries in animal models. Not
long thereafter, the use of stents was reported as an
adjunct to PTRA.11-13 The placement of intravascular
stents in renal arteries has been recommended after PTRA
that has failed as a result of elastic recoil and resistance of
the aortic plaque, dissection, or restenosis, or as a primary
procedure itself.7,16-23 In this study, we evaluated the
technical and clinical results of stent placement in 73
patients with hemodynamically significant atherosclerotic
renal artery stenoses.
MATERIAL AND METHODS
Patient population. Medical records were retrospec-
tively reviewed for this study. Patients undergoing PTRA
and stenting between July 1992 and January 1999 at our
institution were identified with physician billing codes.
During this time frame, 88 Palmaz (Johnson & Johnson
Interventional Systems, Warren, NJ) stents were deployed
into 85 renal artery stenoses (left 43, right 45) in 73
patients. Twelve patients (16%) received bilateral stents.
Of these 12, eight had bilateral ostial stenoses. Stents were
deployed in two patients with a congenital solitary kidney
and in three patients who had had a previous nephrec-
tomy. In four patients the contralateral renal artery was
occluded (bilateral occlusion in one patient). Only one
patient underwent hemodialysis before stent placement.
Patient demographics are shown in Table I. Seventy-one
lesions (84%) were ostial; the remaining 14 (16%) were
nonostial. A stenosis was considered hemodynamically sig-
nificant if there was greater than 50% luminal stenosis or
greater than 15% peak systolic pressure gradient (percent
peak systolic pressure gradient = renal artery peak systolic
pressure/aortic peak systolic pressure × 100) measured
across the stenosis.24 The lesion was considered ostial if it
involved the proximal 5 mm of the renal artery. After
PTRA indications for stenting were a peak systolic pres-
sure gradient greater than 10% remaining across the lesion
or a residual stenosis greater than 30%. Primary stenting
was not performed in this group of patients.
Reasons for renal evaluation were uncontrolled
hypertension in 27 patients (37%) or worsening renal
function in 19 patients (26%). Twelve patients (16%) had
a combination of the two symptoms. All patients in this
series had some degree of hypertension, and many were
considered high-risk surgical candidates because of multi-
ple comorbid illnesses (Table I). Evidence of systemic
manifestations of atherosclerotic disease was present in 58
patients (79%). Renal artery stenosis was diagnosed as an
incidental finding in 15 patients (21%) who were being
evaluated primarily for peripheral vascular disease, cere-
brovascular disease, or coronary artery disease. In this
subset of patients, the decision to treat the renal artery
lesion was a clinical judgment on the basis of the high
degree of stenosis (85% ± 12%) present in the setting of
hypertension requiring 2.8 ± 1 drugs for control. These
15 patients had a mean serum creatinine level of 1.5 ± 0.7
mg/dL. Two of the 15 had development of intrastent
restenosis at 3 months and 17 months requiring repeat
angioplasty. No patients in this subset required dialysis;
indeed, all had either improvement or no change in their
creatinine level. The treatment of renal artery stenosis
with PTRA and stenting was considered for patients with
poorly controlled hypertension (systolic blood pressure ≥
160 mm Hg or diastolic blood pressure ≥ 90 mm Hg)
with two or more medications, renal artery stenosis that
was considered preocclusive, or renal insufficiency (serum
creatinine level ≥ 1.5 mg/dL; Emory University Hospital
laboratory standard). Fifty patients (68%) had abnormal
baseline serum creatinine levels. Serum creatinine levels
were 1.5 to 2 mg/dL in 23 patients (32%), 2.1 to 3.0
mg/dL in 13 (18%), 3.1 to 4.0 mg/dL in 8 (11%), and
greater than 4.0 mg/dL in 6 (8%). All patients referred
with renal insufficiency who were found to have renal
artery stenosis amenable to an endovascular approach
underwent PTRA with stent placement when appropri-
ate. Follow-up data collected included blood pressure
(BP), oral antihypertensive therapy, serum creatinine lev-
els, restenoses, other interventions, need for dialysis, and
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Table I. Patient profile
Characteristic Value
Men/women (%) 33/40 (45/55)
Age (y) 67.8 ± 9.5 (range, 40-86)
Risk factors
Tobacco use 25 (34)
Ischemic heart disease* 43 (59)
Diabetes mellitus† 12 (16)
Peripheral vascular disease‡ 49 (67)
BP (mm Hg)
Systolic 166 ± 29
Diastolic 84 ± 16
Patients with systolic ≥ 160 and/or 57 (78)
diastolic ≥ 90 mm Hg
No. of antihypersensitive drugs 2.8 ± 1.1
Three or more antihypersensitive drugs 39 (53)
Serum creatinine level (mg/dL) 2.2 ± 1.4
Patients with Cr ≥ 1.5 mg/dL 50 (68)
Cr, Serum creatinine level.
Mean ± SD.
*Ischemic heart disease—evidence in medical record of documented angina
pectoris, coronary artery bypass or angioplasty, congestive heart failure,
myocardial infarction.
†Diabetes mellitus—either insulin-dependent or non–insulin-dependent on
oral hypoglycemic therapy.
‡Peripheral vascular disease–history of prior medically treated peripheral
arterial occlusive disease, or a history of surgery for correction of athero-
sclerotic disease.
death. Clinical success was achieved if the patient derived
benefit from the stenting, manifest as an improvement in
blood pressure; a reduction in number of antihyperten-
sive medications; or an improvement or no change in
renal function. Improvement in renal function was
defined as a 20% decrease in the serum creatinine level
after stent placement compared with the pre-stent base-
line level. A consistent 20% increase in serum creatinine
from baseline defined worsening function, and creatinine
levels within 20% of baseline were considered to be
unchanged. Long-term clinical data were available on 69
(95%) patients for an average of 20 ± 17 months (range,
9-72 months). Follow-up information was collected from
inpatient and outpatient chart review at Emory University
Hospital and by contacting the patients, their family, and
their referring physician. It was our policy to repeat
angiography in patients in whom improvement in hyper-
tensive control or renal function initially occurred and
then later deteriorated. Routine imaging was not system-
atically performed.
Endovascular techniques. All endovascular proce-
dures were performed in an interventional suite by expe-
rienced vascular radiologists. After gaining percutaneous
arterial access, a selective digital renal arteriogram was
performed with either nonionic low osmolar iodinated
contrast or CO2. The lesion(s) was localized by use of a
5F catheter, and a road map image was created. Pressure
gradients and percent stenosis were determined. An 8F
renal artery guiding catheter was positioned at the renal
artery orifice, through which an appropriately sized bal-
loon was passed and angioplasty was performed. When
the decision to place a stent was made, Palmaz stents
were mounted on the delivery balloon, and the balloon
and guiding catheter were placed across the stenosis. The
guiding catheter was then retracted, and the stent was
deployed. Patients were given systemic anticoagulants
during the interventions and received 50- to 100-µg
aliquots of nitroglycerin directly into the renal artery
before each catheter or guide wire exchange as prophy-
lactic treatment against vasospasm. Technical success was
defined as safely crossing and dilating the stenosis with
no major morbidity, a residual stenosis of less than 30%,
or a peak systolic pressure gradient of less than 10%, all
in compliance with the Society for Cardiovascular and
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Interventional Radiology Standards of Practice guide-
lines.24
Statistical analysis. Descriptive data are expressed as
mean ± 1 SD. Differences between groups were calculated
by the Student t test for continuous variables. Probability
values less than .05 were considered statistically signifi-
cant. Kaplan-Meier survival analysis was performed. An
SAS statistical package was used for analysis (version 5.0;
Abacus Concepts, Berkeley, Calif).
RESULTS
Technical results. Initial stent insertion was success-
ful in 76 of 85 renal arteries, for an immediate technical
success rate of 89% as indicated by little or no residual
pressure gradient and negligible postprocedural residual
stenoses. The preprocedural mean diameter stenosis was
86% ± 12%. Failure to completely cover an ostial lesion
occurred in three patients because of distal placement of
the stent. This misplacement was seen at the time of stent-
ing; consequently a second overlapping stent was placed
successfully over the lesion or arterial ostium. In one
patient, small filling defects within the stent were seen on
completion angiography. Urokinase (250,000 units
administered over 10 minutes) was infused with complete
resolution of the defects, thus indicating the presence of
intrastent thrombus. With these four corrective measures,
the postprocedure technical success rate was 94% (80 of
85 arteries). 
Problems during the procedure were encountered in
five patients. In one failed procedure, an unsuccessfully
dilated 90% stenosis was complicated by subintimal guide
wire dissection and subsequent renal artery occlusion. The
patient underwent successful immediate operative revascu-
larization. In another patient, after dilation and stenting of
an occluded proximal renal artery lesion, urokinase was
infused overnight in an attempt to increase the poor arte-
rial flow after stent placement. Arteriography performed
after the overnight thrombolytic infusion demonstrated
persistent sluggish flow because of more distal renal arter-
ial and parenchymal disease. No further intervention was
considered appropriate in this case. In two failed proce-
dures, attempts to stent a residual stenosis after PTRA
were unsuccessful because the stents slipped off the bal-
loons on which they were mounted. In both cases the
Table II. Clinical variables before and after intervention (short-term)
Variable Before PTRA/stent After PTRA/stent P value
Systolic blood pressure (mm Hg) 166 ± 29 141 ± 19 < .001
Diastolic blood pressure (mm Hg) 85 ± 16 76 ± 12 < .001
No. of antihypersensitive medications 2.8 ± 1.1 2.3 ± 1.2 .01
Serum creatinine level (mg/dL) 2.2 ± 1.4 2.0 ± 1.3 NS
Serum creatinine level (mg/dL) in patients with renal 2.7 ± 1.4 2.4 ± 1.3 NS
insufficiency (Cr ≥ 1.5 mg/dL)
Cr, Serum creatinine level; NS, no significant between-group difference.
Mean ± SD.
stents were recaptured and deliberately deployed in the
external iliac artery. The patients were observed with no
compromise in iliac artery blood flow; no further renal
therapy was attempted. The fifth technical failure took
place after inadvertent subintimal guide wire placement. A
renal artery dissection was noted with compromised flow
to the kidney. The contralateral kidney had already been
successfully stented and the guide wire removed; therefore
no further treatment was performed.
Treatment of restenosis. Routine follow-up imaging
was not routinely performed in this population. Angi-
ography was performed for worsening hypertension or
recurring renal insufficiency in 15 patients (20.5%) who
had initially responded favorably to renal artery stenting.
There were 14 intrastent restenoses in 14 renal arteries of
10 patients occurring at 11.3 ± 10.3 months. Eleven (79%)
of the restenotic lesions were ostial. Fifty percent of the
lesions were successfully treated by angioplasty alone (n =
4), with stent implantation (n = 3), and surgical revascu-
larization (n = 2). No further treatment was recommended
in five patients who had only moderate degrees of resteno-
sis. Figs 1 through 7 illustrate one such complicated case in
a patient who had undergone previous bilateral PTRA
alone and presented with recurrent disease, eventually
requiring a bilateral aortorenal artery bypass graft.
Clinical results. After renal artery stenting, there was
a statistically significant overall improvement in both sys-
tolic and diastolic arterial pressures and in the reduction of
the number of antihypertensive medications (Table II). At
latest follow-up, 61 patients (84%) had a systolic BP less
than or equal to 160 mm Hg, and 65 (89%) had a diastolic
BP less than or equal to 90 mm Hg. Four patients (5.5%)
were eventually allowed to discontinue taking medications
altogether. Overall, postoperative renal function measured
by mean serum creatinine level did not change. Likewise,
in the subset of 50 patients with renal insufficiency (crea-
tinine level ≥ 1.5 mg/dL), the mean postoperative creati-
nine level was also not significantly changed. Table III
demonstrates the clinical results of the patients with pre-
operative renal insufficiency by incremental baseline serum
creatinine level. At serum creatinine levels less than 4.0
mg/dL, most patients either had levels that improved or
remained unchanged. Only those in the patient cohort
with extreme renal dysfunction (> 4.0 mg/dL) did not
have any benefit from endovascular intervention.
Long-term follow-up of renal function was available
on 69 patients (95%) at 20 ± 17 months. Serum creatinine
level decreased by more than 20% in 16 patients (22%).
Renal function was unchanged (positive or negative
change ≤ 20%) in 35 patients (48%) and deteriorated
(increase of > 20%) in 18 patients (25%). Nine patients
(12%) required dialysis after the procedure, five of whom
had preoperative serum creatinine levels of more than 4.0
mg/dL. Two (3%) of those with deterioration in renal
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Fig 1. Survival (dialysis-free) curve of 69 patients after renal
artery stent deployment.
Fig 2. A, Preoperative angiogram shows bilateral renal artery
stenoses in 65-year-old woman with increasing BP and serum cre-
atinine level. B, Angiogram after dilation of right renal artery with
5-mm balloon, residual pressure gradient of 12 mm Hg.
A
B
function eventually underwent successful surgical renal
revascularization after the endovascular procedure. In the
group of nine patients requiring dialysis, the serum creati-
nine level before PTRA and stent placement was 4.5 ± 1.6
mg/dL (range, 2.3-6.8 mg/dL). Dialysis was initiated at
17.4 ± 13.0 months (range, 0.8-39.1 months). Cumula-
tive survival (dialysis-free) is presented in Fig 8. 
Complications. One perioperative death occurred
because of the renal intervention (30-day mortality rate of
1.4%). This patient was diagnosed with anuria (serum cre-
atinine level 7.5 mg/dL) after nephrectomy. At angiogra-
phy she was found to have an occluded renal artery. After
angioplasty there was persistent sluggish flow through the
renal artery. Urokinase was infused in an attempt to
increase the flow, but the result was unsatisfactory because
of more distal and diffuse atherosclerotic disease of the
renal artery. The patient had a cerebral hemorrhage after
thrombolytic therapy and subsequently died. This was
considered a technical failure for the purposes of this
study. In the first 12 months, records show that four
patients (5.5%) died, two as a result of complications of
systemic atherosclerotic disease. 
The incidence of major complications in this study was
9.4%. One patient had renal artery thrombosis necessitat-
ing an urgent, albeit successful, surgical revascularization.
In another patient, the renal artery developed a pinhole-
sized leak secondary to a balloon rupture. Contrast
extravasation was noted from the renal artery, and the
leakage ceased after balloon tamponade and stent deploy-
ment. The artery remained patent with no surgical proce-
dure or blood transfusion required. In addition, there
were six complications associated with arterial access.
Three patients had development of acutely ischemic limbs
after the intervention necessitating operative repair or
revascularization. One femorofemoral bypass graft throm-
bosed and was successfully treated with urokinase.
Hematomas requiring surgical evacuation developed at
two puncture sites. 
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DISCUSSION
After the first renal artery angioplasty by Grüntzig et
al3 in 1978, catheter-based revascularization has become
widely accepted for the treatment of atherosclerotic reno-
vascular disease. The morbidity of a major surgical proce-
dure is avoided in a population of patients who are often
elderly, have azotemia, and are debilitated because of
other manifestations of systemic atherosclerotic disease.
The concomitant use of stents has been claimed to be supe-
rior to angioplasty alone in maintaining luminal diameter
and decreasing the translesion pressure gradient.18
Nonetheless, the incidence of restenosis is of concern, rang-
ing from 11%16 to 44%5 at 2 years. Although one can be crit-
Fig 3. Right renal artery after guide wire was removed noted to
have postangioplasty dissection. Left renal artery was dilated with
5-mm balloon.
Fig 4. A and B, Angiogram obtained 4 months later when
patient had recurrent hypertension after initial improvement
shows bilateral restenoses.
A
B
ical of the disappointing restenosis rates and technical suc-
cess rates that are inferior to surgery, it is important to
remember the low overall survival rate in patients with severe
atherosclerotic disease. Therapeutic goals and result expec-
tations cannot be the same as in patients who are younger,
have recent onset of hypertension, and have normal renal
function. Open surgical renal revascularization is a proven
standard, albeit not one without significant risk, with mor-
bidity and mortality rates ranging from 7% to 44%.25-27
During the time frame of this study, Palmaz stents were
the only type of balloon-expandable stents obtainable.
Currently, there is a wider variety of stents available for use,
although to date, none have demonstrated superior efficacy.
Most renal artery lesions meeting the indications for stent-
ing in this report were ostial (84%) because of the high
prevalence of systemic atherosclerotic disease and the infe-
rior results of PTRA in this location. Additionally, with the
advent of stent deployment for ostial renal artery lesions,
most of our patients do receive stents because of the higher
technical success achievable. With stenting of mainly ostial
renal artery lesions we have enjoyed a higher procedural
success rate (94% compared with 35%); however, there has
been no increase in long-term clinical benefit when the
cohort presented here is compared with prior work.2
Critical ostial lesions have presented a challenge to the
interventionalist because of the recoil and resistance of the
aortic plaque. All patients underwent predilation of their
stenosis with an appropriately sized 4- to 8-mm diameter
balloon. Results previously reported from our institution
showed no additional benefit to increasing the balloon size
in relation to the normal vessel diameter.2 Stents were posi-
tioned to protrude 1 to 2 mm into the aortic lumen. In
three patients a second stent was placed proximal to the first
stent to ensure complete coverage of the aortic plaque.
Because the misplacement of the stent was recognized
immediately and corrected with the more proximal stent,
these three patients were considered technical successes.
Thus, our technical success rate for this procedure was high,
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Table III. Relationship of clinical results and serum creatinine levels before endovascular revascularization in 50
patients with renal insufficiency
Serum creatinine level 
before PTRA/stent (mg/dL) Improved Unchanged Worse Follow-up (mo) No. requiring dialysis
1.5-2.0 (n = 23)* 6 13 3 19.6 ± 19.6 1
2.1-3.0 (n = 13) 3 7 3 15.5 ± 15.0 1
3.1-4.0 (n = 8)* 6 0 1 17.9 ± 15.4 1
> 4.0 (n = 6)* 0 0 5 12.1 ± 12.6 5
Mean ± SD
*No follow-up data available on one patient.
Fig 5. Angioplasty of left renal artery with 5-mm balloon.
Fig 6. Postoperative angiogram after deployment of stent in left
renal artery. No pressure gradient across stent.
reaching 94%. This is consistent with the high success rates
reported by others.*
Myointimal hyperplasia or progression of atheroscle-
rotic disease may cause intrastent stenosis. True restenosis
rates are impossible to calculate from our data because
only 22 patients underwent repeat renal angiography.
Angiography was not performed systematically but only in
patients whose hypertension or renal function initially
improved but later deteriorated or who were restudied
during evaluation for other peripheral vascular symptoms
or heart disease. With these criteria, restenosis was present
in 14 of the 22 patients evaluated. This high incidence of
restenosis was to be expected because the patients under-
went repeat imaging out of concern for possible resteno-
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sis. Patients with asymptomatic renal artery restenoses
would not have otherwise been detected, unless the
restenosis was discovered as an incidental finding during
angiography performed for other reasons.
The clinical benefit in hypertension control in a
noncontrolled, retrospective study such as ours also
needs to be interpreted with caution. The preprocedural
and postprocedural blood pressures were monitored for
changes, as were the number of medications the patient
was taking for control, with statistically significant
reductions seen in both. Although other investigators
have reported a similar clinical benefit after stent-
ing,7,15,16,20,29,30 it is unclear in our patients whether
this benefit is due to more appropriate medical control
or to the intervention. As we stated in a prior study, it is
theoretically possible that clinical benefit occurred in
spite of restenosis.2 Furthermore, patients were not con-
sidered for renal angioplasty or stenting if they required
surgery for aortoiliac occlusive disease or abdominal aor-
tic aneurysm. What is also lost in a retrospective study is
the number of patients who had a hemodynamically sig-
nificant renal artery stenosis but were not considered
candidates for PTRA/stenting. This was because the
interventionalist considered either the procedure too
difficult or the risk to the patient excessive, or patients
were eliminated from consideration by the referring
physician, the patient, or the patient’s family.
In a similar study, White et al7 reported 6-month
outcomes in a cohort of 100 patients with stents and
observed continued lowering of the BP. Blum et al6
reported that 16% of their patients had long-term (27
month) normalization of BP. As nonprimary care spe-
cialists working in a tertiary referral environment, we do
not often have the benefit of long-term patient follow-
up. It is assumed, however, that each patient continues
Fig 8. The same woman presented 5 months later (9 months
from her original intervention) with uncontrolled hypertension.
Angiogram showing moderate right renal artery intrastent steno-
sis and severe left intrastent stenosis. She underwent a successful
bilateral renal aortorenal bypass graft.
Fig 7. A, Angioplasty of right renal artery with 6-mm balloon.
B, Stent deployed close to branch vessels.
A
B
*References 7, 13, 16, 18-20, 23, 24, and 28.
to be treated by the same primary care physician after
the intervention. A statistically significant reduction in
the number of medications being used for BP control
was observed, which is clinically significant as well, given
the reduction in both systolic and diastolic blood pres-
sures. Changes in the dose of each medication were not
consistently documented and thus not included in analy-
sis. It was also impossible in this study to determine
whether an improvement in blood pressure was due to
the interventional procedure, better drug compliance by
the patient, a better drug regimen by the prescribing
physician, or a combination. Although other studies
have observed higher rates of unchanged (36%-
67%)13,16,17 or improved (29%-36%)13,16,17 renal func-
tion (defined as a 20% improvement in serum creatinine
value after stent placement), the baseline renal function
in these reports is usually better than that present in our
patients. Indeed, the mean serum creatinine level
reported by Henry at al16 before stent placement in 210
patients was 1.39 ± 0.70 mg/dL, compared with a level
of 2.2 ± 1.4 mg/dL in our series.
Because the natural history of atherosclerotic renal
vascular disease is progression to occlusion with immi-
nent kidney failure, a slowing of the rate of deterioration
and preservation of the remaining renal function are
realistic goals of renal revascularization in patients with
this disease. As previously stated, it is unclear whether a
lack of change in serum creatinine level truly represents
stabilization of renal function or a retardation of the rate
of progression. Indeed, Harden et al17 demonstrated
that in patients with two functioning kidneys and unilat-
eral renal artery stenosis, the rate of decline in renal
function was decreased after stent deployment. This was
indicated by analysis of the slope of reciprocal creatinine
plotted against time. Longitudinal analysis, based on
work by Rowe et al30 on the rate of change of renal
function, requires analysis of at least five preprocedural
data points, detailed postprocedural data collection, and
the use of a computer program. The method fits two
intersecting lines to data by computing a least-squares
estimate of the position of the slope change and its 95%
confidence limits. The work of Harden et al17 supports
those who argue that stabilization of renal function or
delay in the progression of functional impairment is
indicative of successful treatment in the azotemic popu-
lation. Additionally, improvement of BP control and
lowering the number of medications needed may lead to
an improvement in renal function. As demonstrated in a
recent large series by Rodriguez-Lopez et al,31 a high
procedural success rate (97.6%) was combined with an
improvement in hypertension without any significant
change in serum creatinine levels. However, the mean
serum creatinine level in their study was 2.0 mg/dL,
with 67% of the patients having a level of 1.5 mg/dL or
less. Their study had excellent follow-up, including clin-
ical examination in 100% of patients and renal artery
duplex scanning and angiography in 76%. Of the 50
patients in our series with preoperative baseline renal
insufficiency, the condition of most remained un-
changed (43%) or improved (32%) after treatment.
More specifically, 86% with a baseline serum creatinine
level of 1.5 to 2.0 mg/dL, 77% with a level of 2.1 to 3.0
mg/dL, and 86% with a level of 3.1 to 4.0 mg/dL had
improved or unchanged renal function. All patients with
severe baseline renal dysfunction (creatinine level ≥ 4.0
mg/dL) went on to require hemodialysis.
This retrospective study demonstrates that experi-
enced interventionalists can successfully perform the
stenting of renal artery stenoses. Although morbidity,
and even death, can occur, percutaneous methods can
play an important role in hypertension control in this
patient population. Although the authors recognize that
surgical revascularization or transaortic endarterectomy
is beneficial in the treatment of renal artery stenosis,
these procedures are not without significant morbidity
and mortality rates. Many patients, such as the ones pre-
sented in this series, may not tolerate a major open sur-
gical revascularization. In patients who undergo
intervention for the control of hypertension, results are
encouraging. In patients for whom the primary reason
for intervention is worsening renal function, the condi-
tions of 70% will improve or their renal function will not
change as measured by serum creatinine levels.
However, in the patients who have unchanged creati-
nine levels after PTRA and stent placement, our data do
not necessarily support any treatment benefit toward
renal salvage in this group. Indeed, the patients in this
series with extreme renal excretory dysfunction did not
benefit from endovascular treatment, emphasizing the
need for a high clinical suspicion of renal artery stenosis
and earlier diagnosis. A prospective, randomized trial
would be necessary to determine any benefit of endovas-
cular intervention on either survival or dialysis-
independence. In this manner the natural history of
untreated renovascular insufficiency may be realized.
The survival of patients with renovascular disease and
renal insufficiency is poor, with 2-year survival reported
as low as 50%. Renal dysfunction can be improved or
stabilized in most patients, and dialysis-free survival may
be prolonged in those with incipient end-stage renal dis-
ease by intervening in patients with significant renal
artery stenosis.
CONCLUSION
This retrospective study demonstrates that the
endovascular treatment of renal arteries is a safe and effec-
tive alternative to surgical management of renal artery
stenosis in patients with poorly controlled hypertension or
deteriorating renal function. High restenoses rates con-
tinue to be the Achilles’ heel of ostial renal artery stenting.
However, most of these patients can be successfully
treated percutaneously. Should strategies for the control of
restenosis become reality, stenting will then become the
primary mode of intervention.
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